KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Receivables (2016 - 2025)

Alnylam Pharmaceuticals' Receivables history spans 17 years, with the latest figure at $777.6 million for Q4 2025.

  • For Q4 2025, Receivables rose 91.85% year-over-year to $777.6 million; the TTM value through Dec 2025 reached $777.6 million, up 91.85%, while the annual FY2025 figure was $777.6 million, 91.85% up from the prior year.
  • Receivables reached $777.6 million in Q4 2025 per ALNY's latest filing, down from $964.8 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $964.8 million in Q3 2025 to a low of $9.1 million in Q2 2022.
  • Average Receivables over 5 years is $359.6 million, with a median of $323.4 million recorded in 2023.
  • Peak YoY movement for Receivables: skyrocketed 5312.39% in 2021, then tumbled 98.3% in 2022.
  • A 5-year view of Receivables shows it stood at $198.6 million in 2021, then grew by 19.84% to $238.0 million in 2022, then skyrocketed by 37.75% to $327.8 million in 2023, then rose by 23.65% to $405.3 million in 2024, then surged by 91.85% to $777.6 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Receivables are $777.6 million (Q4 2025), $964.8 million (Q3 2025), and $567.1 million (Q2 2025).